Antonio Rullan
Impact in
- Ophthalmology top 2%
- Ocular Oncology and Treatments
- Immunology top 10%
- Immunotherapy and Immune Responses
- Immune cells in cancer
- interferon and immune responses
Papers in
- Oncology 13
- Cancer Immunotherapy and Biomarkers 6
- Cancer Cells and Metastasis 3
- CAR-T cell therapy research 3
-
- Immunotherapy and Immune Responses 4
- interferon and immune responses 2
- Immune cells in cancer 2
- Co-authors
- Erik Sahai (6 shared papers)Danielle Park (2 shared papers)Josep M. Piulats (2 shared papers)Nicola Tinari (1 shared paper)Alfonso R. Sánchez-Paulete (1 shared paper)María E. Rodríguez-Ruiz (2 shared papers)Ignacio Melero (2 shared papers)Marc Oliva (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)Frontiers in Oncology (3 papers)Blood (2 papers)Annals of Oncology (2 papers)
- Partner nations
- United KingdomSpainUnited States
In The Last Decade
Antonio Rullan
28 papers receiving 1.0k citations
Antonio Rullan's Hit Papers
Peers
Comparison fields: 5 of 87
- Ophthalmology 172
- Immunology 336
- Oncology 366
- Otorhinolaryngology 45
- Cancer Research 93
Countries citing papers authored by Antonio Rullan
This map shows the geographic impact of Antonio Rullan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Rullan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Rullan more than expected).
Fields of papers citing papers by Antonio Rullan
This network shows the impact of papers produced by Antonio Rullan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Rullan. The network helps show where Antonio Rullan may publish in the future.
Co-authors
The 25 scholars most cited alongside Antonio Rullan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 171 | |
| 2 | Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) Hit paper breakdown → | 2021 | 153 |
| 3 | 2020 | 123 | |
| 4 | 2021 | 93 | |
| 5 | 2010 | 91 | |
| 6 | 2020 | 75 | |
| 7 | 2016 | 65 | |
| 8 | 2019 | 56 | |
| 9 | 2015 | 30 | |
| 10 | 2022 | 27 | |
| 11 | 2019 | 27 | |
| 12 | 2022 | 22 | |
| 13 | 2024 | 19 | |
| 14 | 1956 | 18 | |
| 15 | 2022 | 10 | |
| 16 | 2024 | 10 | |
| 17 | 2024 | 7 | |
| 18 | 2024 | 6 | |
| 19 | 2023 | 6 | |
| 20 | 2025 | 6 |
About Antonio Rullan
Antonio Rullan is a scholar working on Oncology, Immunology, Molecular Biology, Otorhinolaryngology and Surgery, having authored 33 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Head and Neck Cancer Studies (4 papers), Immunotherapy and Immune Responses (4 papers), Cancer Cells and Metastasis (3 papers), CAR-T cell therapy research (3 papers), Virus-based gene therapy research (3 papers), interferon and immune responses (2 papers) and Immune cells in cancer (2 papers). The work is most often cited by research in Ophthalmology (172 citations), Immunology (336 citations), Oncology (366 citations), Otorhinolaryngology (45 citations) and Cancer Research (93 citations). Antonio Rullan has collaborated with scholars based in United Kingdom, Spain and United States. Frequent co-authors include Erik Sahai, Danielle Park, Josep M. Piulats, Nicola Tinari, Alfonso R. Sánchez-Paulete, María E. Rodríguez-Ruiz, Ignacio Melero, Marc Oliva, Kevin J. Harrington and Alan Melcher. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Frontiers in Oncology, Blood and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.